Garry E. Menzel, Director at Adaptimmune Therapeutics PLC (ADAP), sold 47,702 shares at $0.91 ($43K) on 2023-07-10, disclosed to the SEC on 2023-07-10.
Open-market sale of $43k ADAP by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| TCRR | SELL | 2022-12-07 | $32K | — | Filing → |
| TCRR | SELL | 2022-12-05 | $12K | — | Filing → |